Searchable abstracts of presentations at key conferences in endocrinology

ea0029p44 | Adrenal cortex | ICEECE2012

Female patients with primary aldosteronism are diagnosed earlier and have a better outcome

Pallauf A. , Fischer E. , Endres S. , Bidlingmaier M. , Beuschlein F. , Reincke M.

Introduction: Primary aldosteronism (PA) is the most frequent curable form of hypertension. Hypokalemia is a late symptom of PA. Consequently, PA often is not diagnosed for many years. Our aim was to identify clinical and laboratory parameters in a large cohort of PA patients obtained during their first assessment.Methods: 96 consecutive patients prospectively studied since 2008 at the German Conn’s Registry Center in Munich were eligible for this s...

ea0029p288 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Plasma aldosterone to plasma renin ratio on an automated analyzer using two novel chemiluminescence immunoassays

Manolopoulou J. , Bennett A. , Grimminger P. , Fischer E. , Pallauf A. , Reincke M. , Diederich S. , Bidlingmaier M.

Background: Screening for primary aldosteronism (PA) using the aldosterone to renin ratio (ARR) is recommended by clinical practice guidelines in patient groups with a high prevalence as the disease is reported by several authors in more than 10% of essential hypertensives (EH).Methods: Plasma aldosterone concentration (PAC) and direct renin (DR) were measured using two novel automated chemiluminescence assays (IDS-iSYS; Boldon, UK) and compared to the S...

ea0029p815 | Endocrine tumours and neoplasia | ICEECE2012

Differential TNFα -synthesis and signaling in endocrine tumors after treatment with the Tumor-Vascular-Disrupting Agent ASA404 (vadimezan)

Hantel C. , Ozimek A. , Frantsev R. , Scheller F. , Reincke M. , Mussack T. , Beuschlein F.

Recently, we investigated effects of the Tumor-VDA ASA404 in tumor models for neuroendocrine tumors of the gastroenteropancreatic system and adrenocortical carcinoma 24 hours after treatment of BON and NCIh295 tumor bearing mice with ASA404 (A), paclitaxel (P) or the combination (A+P). We detected for BON tumors extensive necrotic areas as well as a significant decrease in cell proliferation, increase of apoptotic cells and reduction of microvessels after A or A+P treatment wh...

ea0020oc4.4 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Development of a novel anti-IGF1 receptor immunoliposomal cancer therapy with enhanced therapeutic efficiency

Hantel Constanze , Lewrick Felicitas , Schneider Sebastian , Zwermann Oliver , Reincke Martin , Peschka-Suss Regine , Beuschlein Felix

Overexpression and aberrant activation of the insulin-like growth factor system plays a key role in tumor cell proliferation and tumorigenesis in many human tumors. Different therapies targeting IGF1-receptor (IGF1-R) have been developed and currently, some of these agents are evaluated in preclinical and early clinical trials with promising results. Moreover, recent studies have demonstrated that combined treatments with doxorubicin, enhance the efficiency of anti-IGF1-R ther...

ea0020p7 | Adrenal | ECE2009

Use of diurnal rhythm in salivary aldosterone to discriminate between bilateral adrenal hyperplasia and aldosterone producing adenoma

Manolopoulou Jenny , Gerum Sabine , Mulatero Paolo , Spyroglou Ariadni , Reincke Martin , Bidlingmaier Martin

Differential diagnosis between bilateral adrenal hyperplasia (BAH) and aldosterone producing adenoma (APA) in aldosteronism remains challenging in many cases due to the high prevalence of incidentalomas during imaging techniques, the limited sensitivity of orthostatic testing and the technical difficulties of adrenal vein sampling (AVS).We investigated circadian variation in salivary aldosterone (SA) in patients with APA (n=22) and BAH (n=2...

ea0020p25 | Adrenal | ECE2009

Towards an aldosterone producing cell line from an aldosterone producing adenoma

Lichtenauer Urs , Zwermann Oliver , Shapiro Igor , Mussack Thomas , Reincke Martin , Beuschlein Felix

To date, the in depth analysis of the key molecular mechanisms involved in functional autonomy and tumor formation in aldosterone producing adenomas has been hampered by the rarity of the disease and the lack of adequate tumor cell lines. Herein, we cultivated a primary cell culture of an aldosterone producing adenoma taken from a 40 year old male patient with a left sided adrenal tumor mass. The cells have been passaged 24 times and still continue to grow after nearly 11 mont...

ea0014p138 | (1) | ECE2007

Initial presentation of patients with acromegaly - analysis of the German acromegaly register

Petersenn Stephan , Reincke Martin , Buchfelder Michael , Franz Holger , Quabbe Hans-Jürgen

Due to its rarity, initial endocrine abnormalities in acromegaly are difficult to investigate in a large cohort, especially with respect to cofounding variables. We searched the German Acromegaly Register for data on the first presentation of patients with acromegaly.Up to November 2005, 1485 patients with acromegaly had been entered into the database. Male patients demonstrated significantly higher random GH (21.0 (0.2–620.0) ng/ml, median (range))...

ea0056p53 | Adrenal cortex (to include Cushing's) | ECE2018

In vitro effects of KCNJ5 mutations on cellular death mechanisms

Prada Elke Tatjana Aristizabal , Gomez-Sanchez Celso E , Reincke Martin , Williams Tracy A

Introduction: Primary aldosteronism (PA) is the most frequent form of endocrine hypertension and is commonly caused by an aldosterone producing adenoma (APA). Germline and somatic mutations in the KCNJ5 gene have been found in up to 40% of APAs and demonstrated to play a crucial role in the pathophysiology of PA.Aim: Here we characterize and investigate the effects of the most common KCNJ5 mutations on cellular death mechanisms based on...

ea0073pep13.5 | Presented ePosters 13: Pituitary and Neuroendocrinology | ECE2021

Cushing’s syndrome and chronotype

Albani Adriana , Zopp Stephanie , Simon Julia , Vogel Frederick , Reincke Martin , Merrow Martha , Theodoropoulou Marily

Patients with Cushing’s syndrome have a poor quality of sleep. However, little is known about their timing of sleep as regulated by the circadian clock, the so called-chronotype. Considering that patients with Cushing’s syndrome lose their rhythmic circadian cortisol secretion and that corticosteroids act as synchronizer of the circadian clock in cells, aim of the study was to determine whether patients with Cushing’s syndrome alter the timing of their sleep com...

ea0073aep45 | Adrenal and Cardiovascular Endocrinology | ECE2021

The role of E47 in patients with endogenous cortisol excess

Zhang Wei , Nowotny Hanna F. , Zopp Stephanie , Bidlingmaier Martin , Reincke Martin , Uhlenhaut Henriette , Reisch Nicole

ContextE47 is a transcription factor mostly known for its role in B and T cell lineage commitment. Recently E47 was identified as a modulator of glucocorticoid receptor target genes, its loss protecting mice from metabolic adverse effects of glucocorticoids. Patients with Cushing’s syndrome (CS) suffer from an endogenous glucocorticoid excess due to tumour formation associated with a variety of metabolic comorbidities seriously affecting patients&#1...